About the book
Antibodies are the lead molecule in diagnostic and therapeutic treatment for various infectious and metabolic diseases. Since the approval of the first antibody in 1986, at present, ~100 FDA-approved antibodies are available in the market. There are several antibodies in the clinical trials and waiting for approval. The current global market for antibody-based drugs is estimated at ~ $100 billion and is projected to be ~ $200 by 2026. Although antibody-based drugs are dominating clinical applications, there are several challenges like a high production cost, short serum half-life, toxicity, immunogenicity, and limited oral drug delivery that still need to be addressed. Next-generation antibodies have unique advantages over traditional antibodies and show great potential for current limitations. The engineering of antibodies and their production host systems enable commercial production at affordable cost and quality.
This book will aim to provide broad information about antibody engineering technologies and their application to diagnostic and therapeutics for various diseases.
